Forxiga debuts in India at fraction of global prices

The Indian diabetes segment continues to buzz with action. Close on the heels of going through with a second brand plan for saxagliptin, AstraZeneca Pharma has launched Forxiga (dapaglifozin), for type 2 diabetes, on the Indian market at a fraction of international prices.

The Indian diabetes segment continues to buzz with action. Close on the heels of going through with a second brand plan for saxagliptin, AstraZeneca Pharma has launched Forxiga (dapaglifozin), for type 2 diabetes, on the Indian market at a fraction of international prices.

Forxiga, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is available at INR43($0.67) per dose for 10mg in India – "competitively" priced with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category